Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed) | PAR 20 263

Opportunity Information: Apply for PAR 20 263

The NIH funding opportunity PAR-20-263, titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," supports R01 research projects that dig into how well-supported (high-confidence) risk factors for complex brain disorders affect neural biology. The main emphasis is on mechanisms that operate within cells (intracellular), between cells (transcellular, including synaptic and glial interactions), and across neural circuits (how networks of neurons and supporting cells function and change). In this FOA, "complex" can mean that risk arises from multiple sources at once, such as many genes acting together (polygenic risk), environmental contributors, or gene-by-environment interactions, and it can also refer to disorders whose functional disruptions are distributed across many brain regions and circuit elements rather than localized to one place.

A key point is that the FOA is not asking applicants to build full disorder models or to recreate a psychiatric or neurological diagnosis in an animal or cell system. Instead, projects should isolate and clarify the neurobiological impact of one or more risk factors. That means focusing on what specific molecular and cellular components are altered, how those components interact, and how they fit into clearly defined biological processes (for example, synaptic signaling, chromatin regulation, protein trafficking, mitochondrial function, immune signaling in the brain, neuronal development, or circuit-level plasticity). The goal is to move from "this variant/exposure is associated with risk" toward "this is the pathway and mechanism that risk factor perturbs," in a way that can ultimately help identify concrete therapeutic targets.

The FOA is open to both hypothesis-generating and hypothesis-testing approaches. Applicants can propose unbiased discovery work (such as systematic profiling or screening methods that map molecular consequences of risk factors) or more directed studies that test specific mechanistic predictions. The experimental platforms are flexible: in vivo, in situ, and in vitro paradigms are all allowed. This includes model organisms, brain tissue-based approaches, and human cell-based systems such as iPSC-derived neurons and glia, organoids, or other relevant cellular assays, as long as the work stays focused on cellular, molecular, and circuit substrates of neural function.

Behavioral tasks and behavioral outcome measures are allowed but are not the centerpiece of what NIH is looking for here. They can be included if they help interpret cellular or circuit mechanisms, but the FOA makes clear that behavior is neither required nor expected. The center of gravity should remain on mechanistic understanding at the levels of molecules, cells, and circuits, and on the biological processes connecting risk factors to functional changes in neural systems.

Another major expectation is strong dissemination of the resulting biological knowledge so it can be reused by the broader research community. The FOA explicitly encourages applicants to describe and share the paradigms, component pathways, and biological processes in enough detail that they can enrich shared or federated data resources. Examples named in the announcement include resources that contribute to the Gene Ontology, Synaptic Gene Ontology, and FAIR Data Informatics principles. In practical terms, this signals that investigators should plan for clear annotation of mechanisms, pathways, and experimental context, with data practices that make results findable and reusable. NIH is trying to close the gap between risk-factor discovery (often driven by genetics and epidemiology), mechanistic biology, and eventual therapeutic target identification.

This opportunity uses the R01 grant mechanism and explicitly does not allow clinical trials. It falls under the NIH health research category and is associated with CFDA number 93.242. Eligible applicants are broad and include many types of U.S. entities (state, county, and local governments; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses), as well as Native American tribal governments and organizations. The FOA also highlights additional eligible applicants such as HBCUs, Hispanic-serving institutions, AANAPISI institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations and regional organizations, reflecting NIH's broad eligibility framework for research proposals aligned with the scientific goals.

Overall, PAR-20-263 is designed for teams that want to take credible brain-disorder risk factors and do the hard mechanistic work of mapping them onto specific intracellular pathways, cell-to-cell interactions, and circuit-level effects, while producing well-annotated, shareable outputs that help the field connect risk to mechanism and, eventually, to intervention strategies.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
• This funding opportunity was created on 2020-08-10.
• Applicants must submit their applications by 2023-07-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 20 263

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: